Latest thyroid cancer Stories
The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New
-- 2Q Revenue Increased 71%, Compared to Prior Year -- SOUTH SAN FRANCISCO, Calif., Aug.
Transaction Marks First Step Toward Creation of a Molecular Diagnostics Subsidiary to Aid in Patient Diagnosis and Management PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc.
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid
The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, report researchers
-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival
The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication.
- Decisions to Cover Afirma for Use in Thyroid Cancer Diagnosis Bring Total Number of "Blues" Covered Lives to More than 10 Million - SOUTH SAN FRANCISCO, Calif., July 3, 2014 /PRNewswire/
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
Thyroid cancer increased from 14th to 5th most common cancer in women over last 20 years Fremont, California (PRWEB) May 19, 2014 The dramatic increase
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.